Mars van’t Veer

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial

Marinus H. J. van Oers, Richard Klasa, Robert Marcus et al. · Blood · 2006 · 592 citations · Full text

High-Dose Methotrexate-Based Chemotherapy Followed by Consolidating Radiotherapy in Non–AIDS-Related Primary Central Nervous System Lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962

Philip Poortmans, Hanneke C. Kluin‐Nelemans, Hanny Haaxma-Reiche et al. · Journal of Clinical Oncology · 2003 · 331 citations

Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification

Estella Matutes, Winfried F. Pickl, Mars van’t Veer et al. · Blood · 2011 · 309 citations · Full text

An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes

Setareh Shamsili, Janet de Beukelaar, Jan W. Gratama et al. · Journal of Neurology · 2006 · 189 citations

Neuro-oncology, Lymphoid Neoplasia, Autoimmune Disease +8